On May 11, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported that an abstract has been accepted for oral presentation at the upcoming European Hematology Association (EHA) (Free EHA Whitepaper) 2023 Congress (EHA) (Free EHA Whitepaper), which will be held in Frankfurt, Germany June 8-11, 2023 (Press release, Actinium Pharmaceuticals, MAY 11, 2023, View Source [SID1234631476]). The abstract includes data from Actinium’s SIERRA controlled phase 3 study comparing the efficacy of Iomab-B based conditioning, a first-in-class targeted radiotherapy, versus physician’s choice of conventional care in older, relapsed/refractory acute myeloid leukemia with active disease. This latest acceptance of the SIERRA trial results at EHA (Free EHA Whitepaper), a major medical conference, is helping spread awareness about the potential of Iomab-B in facilitating transplants for patients who are currently not transplantable.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the EHA (Free EHA Whitepaper) presentation are as follows:

Presentation Title: SIERRA trial results with a targeted radiotherapy, Iomab-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active r/r AML
Session Type/Title: Oral / SCT Clinical
Date and Time: June 10, 11:30am – 12:45pm CET